Orplatna Needs Overall Survival Data For Prostate Cancer Indication – ODAC
Executive Summary
Progression-free survival data for GPC Biotech's Orplatna are flawed and do not justify accelerated approval of the drug, FDA's Oncologic Drugs Advisory Committee concluded July 24